Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 245

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Open access
Xiao, Ling, Salem, Joe-Elie, Clauss, Sebastian, Hanley, Alan, Bapat, Aneesh, Hulsmans, Maarten, Iwamoto, Yoshiko, Wojtkiewicz, Gregory, Cetinbas, Murat, Schloss, Maximilian J., Tedeschi, Justin, Lebrun-Vignes, Bénédicte, Lundby, Alicia, Sadreyev, Ruslan I., Moslehi, Javid, Nahrendorf, Matthias, Ellinor, Patrick T., Milan, David J · 2020 · Circulation

Abstract

Background: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood. Methods: We performed electrophysiology studies on mice treated with ibrutinib to assess inducibility of AF. Chemoproteomic analysis of cardiac lysates identified candidate ibrutinib targets, which were further evaluated in genetic mouse models and additional pharmacological experiments. The pharmacovigilance database, VigiBase, was queried to determine whether drug inhibition of an identified candidate kinase was associated with increased reporting of AF. Results: We demonstrate that treatment of mice with ibrutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflammation. This effect was reproduced in mice lacking Bruton tyrosine kinase, but not in mice treated with 4 weeks of acalabrutinib, a more specific Bruton tyrosine kinase inhibitor, demonstrating that AF is an off-target side effect. Chemoproteomic profiling identified a short list of candidate kinases that was narrowed by additional experimentation leaving CSK (C-terminal Src kinase) as the strongest candidate for ibrutinib-induced AF. Cardiac-specific Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phenocopying ibrutinib treatment. Disproportionality analyses in VigiBase confirmed increased reporting of AF associated with kinase inhibitors blocking Csk versus non-Csk inhibitors, with a reporting odds ratio of 8.0 (95% CI, 7.3–8.7; P <0.0001). Conclusions: These data identify Csk inhibition as the mechanism through which ibrutinib leads to AF. Registration: URL: https://ww.clinicaltrials.gov ; Unique identifier: NCT03530215.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.049210

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 245

Metadata

Authors
Xiao, L., Salem, J.-E., Clauss, S., Hanley, A., Bapat, A., Hulsmans, M., Iwamoto, Y., Wojtkiewicz, G., Cetinbas, M., Schloss, M. J., Tedeschi, J., Lebrun-Vignes, B., Lundby, A., Sadreyev, R. I., Moslehi, J., Nahrendorf, M., Ellinor, P. T., & Milan, D. J.
Venue
Circulation
Published
2020-12-22
Volume
142
Issue
25
Pages
2443-2455
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3094484041
Cited by
245
References
10
FWCI
16.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. https://app.cochat.ai/papers/10.1161/circulationaha.120.049210
The paper
Xiao, L., Salem, J.-E., Clauss, S., Hanley, A., Bapat, A., Hulsmans, M., Iwamoto, Y., Wojtkiewicz, G., Cetinbas, M., Schloss, M. J., Tedeschi, J., Lebrun-Vignes, B., Lundby, A., Sadreyev, R. I., Moslehi, J., Nahrendorf, M., Ellinor, P. T., & Milan, D. J. (2020). Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. https://doi.org/10.1161/circulationaha.120.049210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.